IP Library Granted Patent US 8,178,510
Granted Patent B2
US 8,178,510 · App. 12/710,537 · Granted May 15, 2012

Preparation of thioarabinofuranosyl compounds and use thereof

Assignee: Southern Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,178,510
App. No.
12/710,537
Granted
May 15, 2012
Kind
B2
Abstract

Patients suffering from cancer are treated by being administered a compound represented by the following formula: wherein each R individually is H or an aliphatic or aromatic acyl group; A is selected from the group consisting of wherein X is selected from the group consisting of hydrogen, fluorine, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano and nitro. The above compounds also inhibit DNA replication in mammalian cells.

Claims (21)

1. A method of treating a patient in need of an immunomodulator which comprises administering to said patient an effective amount of at least one compound represented by the formula 1:

wherein each R individually is H, an aliphatic acyl group or an aromatic acyl group;

A is selected from the group consisting of

wherein X is selected from the group consisting of hydrogen, fluorine, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano and nitro wherein said compound is in the D-arabino configuration.

2. The method of claim 1 wherein each R is H.

3. The method of claim 1 wherein A is

4. The method of claim 3 wherein X is H.

5. The method of claim 1 wherein X is H.

6. The method of claim 1 wherein said compound is 1-(4-thio-β-D-arabinofuranosyl)cytosine.

7. The method of claim 1 wherein said compound is 1-(4-thio-β-D-arabinofuranosyl)-5-fluorocytosine.

8. A method of treating a patient suffering from an autoimmune disease which comprises administering to said patient an effective amount of at least one compound represented by the formula 1:

wherein each R individually is H, an aliphatic acyl group or an aromatic acyl group;

A is selected from the group consisting of

wherein X is selected from the group consisting of hydrogen, fluorine, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano and nitro wherein said compound is in the D-arabino configuration.

9. The method of claim 8 wherein each R is H.

10. The method of claim 8 wherein A is

11. The method of claim 10 wherein X is H.

12. The method of claim 8 wherein X is H.

13. The method of claim 8 wherein said compound is 1-(4-thio-β-D-arabinofuranosyl)cytosine.

14. The method of claim 8 wherein said compound is 1-(4-thio-β-D-arabinofuranosyl)-5-fluorocytosine.

15. The compound 1-(4-thio-β-D-arabinofuranosyl)-5-fluorocytosine.

Assignments (1)
CONFIRMATORY LICENSE Recorded May 24, 2024
From: SOUTHERN RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 067516/0635 →
Continuity (7)
Division 11509030 · Aug 24, 2006
Division 10938542 · Sep 13, 2004
Division 10407135 · Apr 7, 2003
Continuation 09493247 · Jan 28, 2000
Continuation PCTUS9916630 · Jul 23, 1999
Provisional Application 60093869 · Jul 23, 1998
Related Publication 20100216797A1 · Aug 26, 2010